Terms: = Bone cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Diagnosis
3 results:
1. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
El-Ghammaz AMS; Gadallah HA; Kamal G; Maher MM; Mohamad MA
Clin Exp Med; 2018 Nov; 18(4):505-512. PubMed ID: 29876769
[TBL] [Abstract] [Full Text] [Related]
2. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
Rossille D; Gressier M; Damotte D; Maucort-Boulch D; Pangault C; Semana G; Le Gouill S; Haioun C; Tarte K; Lamy T; Milpied N; Fest T; ;
Leukemia; 2014 Dec; 28(12):2367-75. PubMed ID: 24732592
[TBL] [Abstract] [Full Text] [Related]
3. A complex karyotype, including a three-way translocation generating a NUP98-hoxd13 transcript, in an infant with acute myeloid leukemia.
Hidaka E; Tanaka M; Matsuda K; Ishikawa-Matsumura M; Yamauchi K; Sano K; Honda T; Wakui K; Yanagisawa R; Nakazawa Y; Sakashita K; Shiohara M; Ishii E; Koike K
Cancer Genet Cytogenet; 2007 Jul; 176(2):137-43. PubMed ID: 17656257
[TBL] [Abstract] [Full Text] [Related]
